NEW YORK and LONDON, Nov. 28, 2017 /PRNewswire/ -- MeiraGTx, a New York and London
About MeiraGTx MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing treatments for ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers, as well as certain neurodegenerative diseases. In addition, MeiraGTx is developing novel gene regulation platforms that promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
Contact:Andy MerrillProsek Partners212-279-3115, ext. 216
View original content:http://www.prnewswire.com/news-releases/meiragtx-to-present-at-barclays-gene-editing--gene-therapy-summit-300562308.html
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All